Fetal RHD Screening

Fetal RHD Screening is a non-invasive test that predicts the RhD blood type of a fetus using cell-free DNA from a pregnant person's blood as early as 11 weeks' gestation. This publicly funded test is designed to guide RhD Immune Globulin (RhIG) treatment in pregnancies at risk of RhD alloimmunization.

Fetal RHD Screening is publicly funded for Ontario residents who:

  • Are RhD negative
  • Do not have anti-D antibodies
  • Are pregnant with one baby 

  • Fetal RHD screening can be done as early as 11 weeks in your pregnancy.

·       This test uses a sample of your blood. During pregnancy, small pieces of genetic material from the placenta circulate in your blood. The lab looks at this material to predict your baby’s RhD blood type.

  • Results are ready in about 10 business days and are sent to your healthcare provider.

  • If your baby is RhD positive, your provider will recommend RhD Immune Globulin (RhIG) later in pregnancy (and after birth) to help prevent complications in a future pregnancy.
  • If your baby is RhD negative, RhIG is not needed.
  • Learn more about Fetal Blood Type Results & Next Steps

  • After delivery, your baby’s RhD blood type will be confirmed using a blood sample from the umbilical cord.

Watch the Fetal RHD Screening Information Video

Download the Fetal RHD Screening Information Guide for Providers

Download the Fetal RHD Screening Information Guide for Pregnant Individuals

Subscribe to PSO Updates

Subscribe to stay informed about the latest PSO news and prenatal screening updates in Ontario.
Virtual educational sessions on prenatal screening and nuchal translucency quality assurance are available upon request for health‑care providers.